Overview Request Sample Pages Request Customization Download PDF
You are viewing: Spain Preimplantation Genetic Testing Market analysis

The Spain Preimplantation Genetic Testing Market was valued at $6.6 Million in 2025 and projected to reach to $9.9 Million by 2030, representing a compound annual growth rate of 8.6%. Spain's preimplantation genetic testing market is positioned for steady expansion through 2030, driven by increasing adoption among Spanish fertility clinics and growing patient awareness of genetic screening benefits.

Spain Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Spain Preimplantation Genetic Testing Market Trends and Insights

  • This 8.6% compound annual growth rate reflects increasing adoption of advanced reproductive technologies across Spanish fertility clinics and healthcare institutions.
  • Spain's strong healthcare infrastructure and progressive regulatory environment support the integration of PGT into assisted reproductive procedures, positioning the country as a key market within Europe's fertility sector. The Spanish PGT market benefits from rising awareness among couples seeking genetic screening before embryo implantation, driven by improved clinical outcomes and reduced miscarriage rates.
  • Spain's aging population and delayed childbearing trends have elevated demand for reproductive technologies that enhance success rates.
  • Between 2025 and 2030, Spain is expected to see increased investment in genetic testing capabilities and expanded access to PGT services across both public and private fertility centers, supporting the market's consistent upward trajectory..

Key Market Statistics

  • CAGR (2025-2030) 8.6% CAGR
  • Market Size, 2025 ~USD 6.6 Million
  • Forecast, 2030 ~USD 9.9 Million
  • Country Spain

Spain Preimplantation Genetic Testing Market Overview

Market Valuation :

Spain's preimplantation genetic testing market is valued at $6.6 million in 2025, with projections reaching $9.9 million by 2030, representing a robust 8.6% CAGR.

Healthcare Infrastructure :

Spain's advanced healthcare system and well-established fertility clinic network provide a strong foundation for PGT adoption and technological integration across reproductive medicine centers.

Regulatory Environment :

Spain's progressive regulatory framework supports innovation in assisted reproductive technologies, enabling faster adoption of preimplantation genetic testing among licensed fertility providers.

Growth Trajectory :

With an 8.6% CAGR, Spain's market growth is driven by increasing awareness of genetic screening benefits, rising infertility rates, and expanding access to advanced reproductive technologies.

Spain Preimplantation Genetic Testing Market Dynamics

  • The country's robust healthcare infrastructure and progressive regulatory environment create favorable conditions for market penetration and technological advancement.
  • Rising infertility rates and improved reimbursement policies are expected to accelerate demand for PGT services across major metropolitan areas and regional fertility centers.
  • Spain's alignment with European healthcare standards further supports market growth and cross-border collaboration opportunities..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Spain's PGT market is valued at $6.6 million in 2025 and is forecast to reach $9.9 million by 2030, representing an 8.6% CAGR.
      • Spain's advanced healthcare infrastructure and progressive regulatory framework drive adoption of preimplantation genetic testing among fertility clinics.
      • Rising awareness of genetic screening benefits and improved clinical outcomes are key growth drivers in Spain's reproductive medicine sector.
      • Spain's aging population and delayed childbearing patterns increase demand for PGT services to enhance assisted reproduction success rates.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Spain Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES1.771.882.022.182.372.592.833.19
      FERTILITY CLINICS5.055.345.696.126.627.187.818.518.4
      HOSPITALS1.271.331.41.51.61.721.8627.4
      OTHER END USERS0.480.50.520.550.590.630.670.726.6
      TOTAL8.579.059.6310.3611.1812.1213.1614.338.3

      Target Audience

      • Fertility Clinic Operators : Spanish fertility centers need market intelligence to assess PGT service expansion opportunities, competitive positioning, and investment requirements within their regional markets.
      • Medical Device Manufacturers : PGT technology providers require Spain-specific market data to identify growth opportunities, regulatory pathways, and distribution strategies for genetic testing equipment and platforms.
      • Healthcare Investors : Investment firms evaluating reproductive healthcare opportunities in Spain need comprehensive market analysis to assess valuations, growth potential, and risk factors.
      • Diagnostic Laboratory Operators : Genetic testing laboratories require market forecasts and competitive analysis to plan service expansion, pricing strategies, and technology investments in Spain's growing PGT sector.
      • Healthcare Consultants : Management consultants advising Spanish healthcare organizations need detailed market data to develop strategic recommendations for reproductive medicine service development and positioning.

      Key Companies in the Spain Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market-Specific Insights : Gain detailed understanding of Spain's unique PGT market dynamics, regulatory landscape, and growth drivers specific to Spanish fertility providers and healthcare institutions.
      • Competitive Intelligence : Identify key players, market share distribution, and competitive strategies within Spain's preimplantation genetic testing sector to inform business development decisions.
      • Investment Opportunity Assessment : Evaluate market potential and growth trajectory through 2030 with precise forecasting data to support investment decisions in Spanish reproductive healthcare ventures.
      • Strategic Expansion Planning : Leverage Spain-specific market data to develop targeted expansion strategies, partnership opportunities, and service offerings aligned with local demand and regulatory requirements.
      • Regulatory & Reimbursement Guidance : Understand Spain's healthcare reimbursement policies, regulatory requirements, and compliance frameworks essential for market entry and operational success.

      Frequently asked questions

      What is the current market size of preimplantation genetic testing in Spain?

      Spain's PGT market was valued at $6.6 million in 2025 and is expected to grow to $9.9 million by 2030.

      What is the projected growth rate for Spain's PGT market?

      Spain's preimplantation genetic testing market is projected to grow at a compound annual growth rate of 8.6% from 2025 to 2030.

      What factors are driving PGT adoption in Spain?

      Key drivers include Spain's advanced healthcare infrastructure, progressive regulatory environment, rising awareness of genetic screening benefits, and demographic trends such as delayed childbearing and an aging population.

      How does Spain's PGT market compare to other European markets?

      Spain's 8.6% CAGR reflects solid growth within Europe's fertility sector, supported by strong healthcare systems and increasing integration of genetic testing into assisted reproductive procedures.

      Which healthcare providers offer PGT services in Spain?

      Both public and private fertility centers across Spain offer preimplantation genetic testing services, with increased investment expected between 2025 and 2030 to expand access and capabilities.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status